Psilocybin is under clinical development by Ceruvia Lifesciences and currently in Phase I for Migraine. According to GlobalData, Phase I drugs for Migraine have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Psilocybin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Psilocybin overview

Psilocybin is under investigation for the treatment of obsessive compulsive disorder, cluster headache syndrome, nicotine dependence, lyme disease, alcohol use disorder (AUD) and migraine headache. The drug candidate is formulated as capsule and administered by oral route. It is a tryptamine alkaloid which is a psychedelic compound acts by targeting 5hydroxy tryptamine 1A and 2A.

It was also under development for major depressive disorder.

Ceruvia Lifesciences overview

Ceruvia Lifesciences carries out the research, development and commercialization of neuro transformational medicines to treat neurological and psychiatric disorders. The company is investigating its pipeline programs including NYPRG-101, a non-hallucinogenic analog of LSD against migraine, cluster headache, opioid and alcohol use disorders; and SYNP-101, a synthetic form of psilocybin for the treatment of the obsessive-compulsive disorder (OCD). It also produces GMP LSD and supplies it to academic research sites and GMP BOL-148. Ceruvia Lifesciences provides treatments for patients, caregivers, payers and health care providers. The company works in collaboration with Yale University, Usona Institute, The Heffter Research Institute, Clusterbusters and New York University (NYU). Ceruvia Lifesciences is headquartered in Greenwich, Connecticut, the US.

For a complete picture of Psilocybin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.